Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan;93(1):56-58.
doi: 10.1002/jmv.26117. Epub 2020 Jun 19.

Remdesivir and tocilizumab: Mix or match

Karolina Akinosoglou  1   2 , Dimitris Velissaris  3 , Dimitris Ziazias  1 , Christos Davoulos  1 , Alexandros Tousis  1 , Konstantinos Tsiotsios  1 , Christina Kalogeropoulou  4 , Alexandros Spyridonidis  5 , Markos Marangos  1   2 , Foteini Fligkou  6 , Charalampos Gogos  1   2
Affiliations
Comment

Remdesivir and tocilizumab: Mix or match

Karolina Akinosoglou et al. J Med Virol. 2021 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
Chest computed tomography showing bilateral infiltrates (A), in line with plain chest X‐ray findings (B). Significant radiologic improvement was noted 5 days later (C).Temporal course of laboratory markers including (D). CRP, ferritin, absolute lymphocyte count, platelet count, SGOT and D‐dimers is shown, in line with administration of RDV and TCZ. Dashed lines: patient 1, continuous lines: patient 2. CRP, C‐reactive protein; RDV, remdesivir; AST, aspartate aminotransferase; TCZ, tocilizumab
See this image and copyright information in PMC

Comment on

References

    1. Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Agoramoorthy G. COVID‐19: consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients [published online ahead of print May 28, 2020]. J Med Virol. 10.1002/jmv.26078 - DOI - PMC - PubMed
    1. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID‐19: a randomised, double‐blind, placebo‐controlled, multicentre trial. Lancet. 2020;395(10236):1569‐1578. - PMC - PubMed
    1. Xu X, Han M, Li T. Effective treatment of severe COVID‐19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970‐10975. http://chinaxiv.org/abs/2020 - PMC - PubMed
    1. Giamarellos‐Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID‐19 patients with severe respiratory failure [published online ahead of print April 17, 2020]. Cell Host Microbe. 10.1016/j.chom.2020.04.009 - DOI - PMC - PubMed
    1. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID‐19: a single center experience [published online ahead of print April 6, 2020]. J Med Virol. 10.1002/jmv.25801 - DOI - PMC - PubMed